The FDA is set to decide whether to fully approve Leqembi, Eisai and Biogen’s Alzheimer’s treatment by July 6, CNBC reported March 6.
Read the full post on Becker's Hospital Review - Healthcare News
FDA expects to rule on full approval for Alzheimer's drug by July
